BILLERICA, Mass.—A new marketing and distribution agreement signed by Millipore Corp. and JPT Peptide Technologies GmbH, a wholly-owned subsidiary of Berlin-based Jerini AG, gives Millipore worldwide, non-exclusive distribution rights for JPT's line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases and proteases. This includes JPT's line of enzyme substrate sets and microarrays, which contain thousands of peptides with annotated phosphorylation/cleavage sites to study enzymatic activities and substrate specificities.
Financial details of the deal are still under wraps, but Dr. Holger Wenschuh, managing director at JPT, notes that he fully expects to see increased sales for his company as a result of the deal as Millipore makes it possible for JPT's products to reach all major geographical and biomedical markets.
"You will realize that JPT is a pretty small, tech-based company, so we are strong in introducing a new technology to the market," Wenschuh says. "Our drawback is that it is not so easy to give our technologies visibility in the marketplace and develop them as products. This agreement should reduce that problem and I would expect to see our revenues increase over the next few years because of this collaboration."
JPT's peptide-based products strongly complement Millipore's existing portfolio of cell signaling reagents and services, according to Rick Ryan, vice president of the drug discovery business unit for Millipore's Bioscience Division. "This will give Millipore customers access to patented high-throughput peptide synthesis and screening platforms, which accelerates research in the field of signal transduction," he says.
"Really, this strengthens our position in the enzyme and drug discovery markets," notes Michael Rashed, strategic marketing manager for Millipore, "and allows both us and JPT to serve the market better. JPT can continue to focus on what it is respected for—continuing to advance their technology and produce new innovations—while we use our existing market penetration worldwide to expand the reach of those products."
Millipore offers a wide range of research products, from specialty reagents and kits to antibodies and molecular biology tools, and it specializes in tools for kinase research. The company also offers ion-channel drug screening services to pharmaceutical companies.
"We applied our peptide synthesis and peptide array technologies to develop a series of tailor-made products and services to address the increasing demand in the field of kinase and protease research," Wenschuh says. "We look forward to expanding the availability of these tools through Millipore's worldwide, dedicated sales channels."